8月能繁母猪存栏环比-0.1%，9月猪价新低 猪价自24.1.17低点震荡回升，8月中旬达年内高点21.06元/kg，此后震荡回落;25年9月17日猪价13.71 元/kg，较24年年末下跌16%。9月26日自繁自养、外购仔猪养殖利润-74元/头、-237元/头;行业整体亏损 或可带来产能去化。8月末我国能繁母猪存栏量4038万头，环比-0.1%。关于25年猪价走势，该行认为年 度均价同比下行，差异在于优秀猪企完全成本持续优化，带来养殖利润超预期。此外25年以来猪企产能 变化节奏、行业二育情况、出栏体重等方面或受相关影响而带来超预期变化，值得重点关注。 智通财经APP获悉，中国银河证券发布研报称，持续重点强调关注生猪养殖行业的攻守兼备布局机会， 基于能繁母猪作用值及养殖效率的考虑，25年猪价同比或呈下行走势;综合考虑政策去产能以及行业亏 损去产能，叠加成本下行带来的优秀猪企利润超预期，重点关注成本边际变化显著、资金面良好的优质 猪企。宠物食品行业处成长过程中，优质企业市占率呈提升趋势。该行建议可关注养殖链后周期，推荐 饲料龙头及动物疫苗相关企业。黄鸡价格与猪价有一定相关性，且考虑自身供给端低位，后续价格存上 ...

Investment Rating - The report indicates a positive investment outlook for the agriculture, forestry, animal husbandry, and fishery sector, highlighting significant profit growth across various sub-sectors [2][11]. Core Insights - The agriculture, forestry, animal husbandry, and fishery sector achieved a substantial year-on-year profit increase of 208% in the first half of 2025, with total net profit reaching 207.8 billion yuan [2][11]. - The sub-sectors with the highest profit growth included seed industry (+1212%), pig farming (+663%), and agricultural product processing (+60%) [2][11]. - The report emphasizes the recovery of profitability in pig farming, driven by improved cost efficiency and increased production volume, despite a slight decline in pig prices [2][17]. - The poultry sector, particularly white feathered chicken, is experiencing pressure due to oversupply and weak demand, while yellow feathered chicken prices have significantly dropped [2][17]. - The pet food industry is noted for its continued growth, with domestic brands gaining market share and profitability, despite challenges in export due to increased tariffs [2][3]. Summary by Sections 1. Overview of the Agriculture, Forestry, Animal Husbandry, and Fishery Sector - The sector's net profit for H1 2025 was 207.8 billion yuan, marking a 208% increase year-on-year [11]. - The second quarter of 2025 also showed a profit increase of 26% compared to the previous year, with notable growth in agricultural product processing and pig farming [15]. 2. Sub-sector Performance 2.1 Pig Farming - The pig farming sector reported a total revenue of 201.9 billion yuan in H1 2025, a 17.9% increase year-on-year, with net profit soaring to 159.24 billion yuan, up 866% [2][17]. - Despite a slight decline in pig prices, the sector benefited from increased production and reduced costs, leading to significant profit improvements [2][17]. 2.2 Poultry Farming - The white feathered chicken sector is stabilizing, with a slight recovery in profitability due to cost improvements, while the yellow feathered chicken sector faces significant price declines [2][17]. 2.3 Pet Food - The pet food sector saw a revenue increase of 21.4% in H1 2025, driven by domestic brand growth and improved profitability [2][3]. 2.4 Animal Health - The animal health sector experienced a revenue increase of 26.44% in H1 2025, with net profit rising by 68.35% [4]. 2.5 Feed - The feed sector reported a revenue increase of 13.3% in H1 2025, with net profit up 29.5% [4]. 2.6 Seed Industry - The seed industry faced challenges with a revenue decline of 9.7% in H1 2025, attributed to falling grain prices [4]. 3. Investment Analysis - The report suggests that the pig farming industry is entering a phase of stable, high-quality development, with potential for significant profit stability and valuation reassessment for leading companies [3][5]. - The pet food sector is expected to continue its long-term growth trajectory, supported by increasing pet ownership and spending [3][5].

Investment Rating - The report maintains a positive outlook on the agriculture, forestry, animal husbandry, and fishery industry, indicating a "Buy" rating for the sector [2]. Core Insights - In the first half of 2025, the listed companies in the livestock sector experienced a significant recovery in profitability, with a total net profit of 20.78 billion yuan, representing a year-on-year increase of 208% [3][14]. - The sub-industries with the highest profit growth included seed industry (+1212%), pig farming (+663%), and agricultural product processing (+60%) [3][15]. - The report highlights a notable divergence in performance among companies within the sector, driven by industry dynamics and operational conditions [3]. Summary by Sections 1. Overview of the Agriculture, Forestry, Animal Husbandry, and Fishery Sector - The agriculture, forestry, animal husbandry, and fishery sector's net profit for the first half of 2025 reached 20.78 billion yuan, a substantial increase of 208% year-on-year [14]. - The second quarter of 2025 also showed a continued growth trend, with a net profit of 10.84 billion yuan, up 26% year-on-year [18]. 2. Sub-sector Performance Review and Investment Strategy 2.1 Pig Farming - The pig farming sector reported a total revenue of 201.9 billion yuan in the first half of 2025, a year-on-year increase of 17.9%, with net profit reaching 15.92 billion yuan, up 865.5% [21]. - Despite a slight decline in pig prices, companies improved profitability through increased volume and reduced costs, with average breeding costs down by 7.2% [21][33]. 2.2 Poultry Farming - The white feather chicken segment showed signs of stabilization, with revenue growth of 0.6% year-on-year, while the yellow feather chicken segment faced significant price declines, leading to a sharp drop in profitability [3][21]. 2.3 Pet Food - The pet food sector saw a revenue increase of 21.4% year-on-year, driven by domestic brand growth and a favorable pricing environment [3][21]. 2.4 Animal Health - The animal health sector experienced a recovery in demand, with total revenue of 8.61 billion yuan, reflecting a year-on-year increase of 26.44% [5][21]. 2.5 Feed - The feed sector's revenue reached 81.91 billion yuan, up 13.3% year-on-year, benefiting from improved profitability in livestock farming [5][21]. 2.6 Seed Industry - The seed industry faced challenges with a revenue decline of 9.7% year-on-year, attributed to falling grain prices and reduced planting enthusiasm among farmers [5][21]. 3. Investment Analysis and Recommendations - The report suggests that the pig farming industry is entering a phase of stable, high-quality development, with potential for significant profit recovery and valuation reassessment for leading companies [4][6]. - The pet food sector is expected to maintain strong growth, supported by increasing pet ownership and spending per pet [4][6].

Core Viewpoint - TianKang Biological has reported strong financial results for the first half of the year, with significant growth in revenue and net profit, alongside improved cash flow and reduced debt ratio [1][3]. Financial Performance - The company achieved operating revenue of 8.847 billion yuan, a year-on-year increase of 10.68% [1] - The net profit attributable to shareholders reached 338 million yuan, up 22.27% year-on-year [1] - The operating cash flow doubled to 1.619 billion yuan, a 109.44% increase compared to the same period last year [3] - The asset-liability ratio decreased to 47.03%, down 4.46 percentage points from the end of last year [3] Profitability Metrics - The weighted return on equity was 4.73%, an increase of 0.49 percentage points year-on-year [3] - The gross profit margin was 12.07%, up 0.58 percentage points year-on-year [3] - The net profit margin improved to 4.63%, an increase of 1.13 percentage points year-on-year [3] Segment Performance - The second quarter revenue was 4.666 billion yuan, with a quarter-on-quarter growth of 11.63% [5] - The net profit for the second quarter was 190 million yuan, reflecting a quarter-on-quarter increase of 28.35% [5] - The average self-breeding cost for pigs decreased to 12.55 yuan/kg, down from 13.63 yuan/kg at the end of last year [5] - The plant protein and oil processing business saw a revenue increase of 97.60% to 1.449 billion yuan [5] - The corn storage business revenue rose by 72.32% to 1.305 billion yuan [5] Business Outlook - The company plans to acquire 51% of Qiangdu Livestock, a significant player in the local pig farming industry, which is expected to enhance its market position and reduce breeding costs [6] - The latest rolling P/E ratio for TianKang Biological is 12.95, which is relatively low compared to peers in the pig farming sector [6]

Group 1 - The core stock price of Reap Bio as of August 22, 2025, is 23.28 yuan, down 0.51% from the previous trading day, with a trading volume of 96,700 hands and a transaction amount of 224 million yuan [1] - Reap Bio's main business includes veterinary medicine and pet healthcare, with product lines such as animal vaccines, chemical drugs, and feed additives, and the company is actively expanding into the pet healthcare market [1] - The company forecasts a net profit attributable to shareholders for the first half of 2025 to be between 244 million yuan and 277 million yuan, representing a year-on-year growth of 50% to 70%, driven by rapid expansion in the pet healthcare sector and overseas market development [1] Group 2 - On the funding flow side, Reap Bio experienced a net outflow of 12.61 million yuan in main funds on the day, while there was a net inflow of 1.25 million yuan in the past five days [1]

Core Viewpoint - The company reported a mixed performance in its 2025 interim results, with slight revenue growth but a significant decline in net profit, particularly in the second quarter where the net profit was negative [1][3]. Financial Performance - The company's revenue showed a slight increase, while the net profit for Q2 was negative at -0.16 billion yuan, reflecting a quarter-on-quarter change of -120.99% [1]. - The net profit margin decreased from 20.21% in the first half of 2024 to 9.47% in 2025, and the gross profit margin fell from 57.92% to 52.24% [3]. - Return on equity dropped by 1.14 percentage points to 1.14%, indicating a significant pressure on profitability [3]. Operational Efficiency - The company improved its inventory management, with inventory turnover days decreasing by 42.16% to 178.73 days compared to the same period last year [6]. - However, the net cash flow from operating activities declined by 32.06% to 0.89 billion yuan, indicating weakened cash generation ability [6]. - The asset-liability ratio for the first half of 2025 was 16.78%, down by 3.72 percentage points year-on-year, suggesting a reduction in financial leverage [6]. Institutional Holdings - The number of institutional investors holding shares in the company plummeted from 154 to 7, reflecting a significant decrease in investor confidence [9]. - The company's market capitalization peaked at 350.82 billion yuan on August 10, 2020, but has since fallen to 101.84 billion yuan, requiring a 244.50% increase in stock price to return to its historical high [9].

Core Viewpoint - The company plans to utilize idle raised funds for cash management, not exceeding RMB 260 million, to enhance fund efficiency while ensuring the normal operation of fundraising projects and maintaining fund safety [1][2][8] Summary by Sections Investment Purpose - The company aims to improve fund efficiency and increase shareholder returns by managing temporarily idle raised funds, ensuring it does not affect the progress of fundraising projects [5][7] Fund Source and Limit - The company will use up to RMB 260 million of idle raised funds for cash management, which can be rolled over within the specified limit [2][5] Investment Duration - The investment period is valid for 12 months from the date of the board's approval [5][6] Investment Method - The company will invest in high-security, liquid products such as structured deposits, time deposits, and large certificates of deposit, ensuring compliance with relevant regulations [5][6] Impact on Daily Operations - The cash management of idle funds will not affect the normal operation of fundraising projects and is expected to enhance overall performance and shareholder returns [7][8] Approval Process - The proposal for cash management has been approved by the board and supervisory board, complying with legal and regulatory requirements [8]

Summary of Key Points Core Viewpoint - The company intends to utilize idle raised funds for cash management to enhance fund efficiency and shareholder returns while ensuring that it does not affect the ongoing investment projects or the normal operations of the company [1][6]. Group 1: Fundraising and Usage - The company raised a total of RMB 1,227.45 million from its initial public offering (IPO) by issuing 105 million shares at a price of RMB 11.69 per share, with a net amount of RMB 1,141.73 million after deducting issuance costs of RMB 85.72 million [1][2]. - The total investment amount for the projects funded by the IPO is RMB 1,799.19 million, with RMB 1,747.03 million allocated from the raised funds [2]. - Due to a lower-than-expected net amount from the IPO, the company adjusted its investment projects, excluding certain projects and reallocating funds to ensure efficient use [2][3]. Group 2: Cash Management Plan - The company plans to use up to RMB 260 million of idle raised funds for cash management, ensuring that it does not impact the investment projects or the company's operations [3][5]. - The investment period for the cash management is valid for 12 months from the board's approval date, with a focus on low-risk, high-liquidity investment products [3][4]. - The income generated from cash management will be used to supplement any shortfall in the investment amounts for the projects and will be returned to the raised funds account upon maturity [4][6]. Group 3: Impact on Operations - The cash management of idle funds is expected to improve the efficiency of fund usage without affecting the normal progress of investment projects or the company's core business [4][6]. - By managing idle funds effectively, the company aims to achieve additional investment returns, thereby enhancing overall performance and providing greater returns to shareholders [4][6]. Group 4: Compliance and Approval - The cash management plan has been approved by the company's board and supervisory board, complying with relevant laws and regulations [5][6]. - The company will adhere to strict risk control measures and disclose information as required by regulatory authorities [4][6].

Summary of Conference Call Records Industry Overview - The conference call discusses the **pig farming industry** in the context of the "anti-involution" policy aimed at addressing low-price disorderly competition and promoting supply-side reforms [1][2][7]. Key Points and Arguments 1. **Anti-Involution Policy**: The policy aims to control basic production capacity, breeding sow inventory, and the weight of pigs at market release, thereby preventing drastic fluctuations in production and prices [1][8]. 2. **Supply-Side Reforms**: The reforms are expected to lead to an optimized supply structure in the pig farming industry, enhancing overall efficiency and resource conservation [1][3]. 3. **Economic Environment**: The current economic environment is characterized by a transition from financial re-inflation to food re-inflation, with significant changes in household savings and investment behaviors [4][5]. 4. **Inflation Understanding**: Inflation levels should be understood through both supply reform and demand stimulation, with a focus on supply-side adjustments before demand-side interventions [6]. 5. **PPI Impact**: A narrowing decline in the Producer Price Index (PPI) is anticipated to have a strong impact on asset allocation strategies [6]. Specific Measures in Pig Farming - The anti-involution measures include controlling the number of breeding sows, reducing the weight of pigs at market release, and timely reporting of production data [1][8]. - The goal is to prevent overproduction and stabilize prices, which is crucial for maintaining profitability in the sector [7][14]. Industry Challenges and Responses 1. **Overcapacity Issues**: The pig farming industry has faced overcapacity challenges, with a slow exit of outdated production capacity despite profitability since May 2024 [2][9]. 2. **Animal Health Industry**: The veterinary medicine and vaccine sectors are experiencing intense competition, with many companies reporting declining performance [2][10][16]. 3. **Market Dynamics**: The market for veterinary products is expected to improve as the anti-involution policy encourages innovation and higher standards for new product approvals [16][18]. Future Projections - The breeding sow inventory is expected to gradually decrease, impacting pig supply and prices in the second half of 2026 [14]. - Short-term price pressures are anticipated due to seasonal factors, but overall price stability is expected as supply adjustments take effect [15]. Investment Opportunities - Companies with efficiency advantages in pig farming and leading firms in the veterinary medicine sector are identified as having high investment value [19]. - Specific companies such as Keqian Bio, Ruipu Bio, and Huisheng Bio are highlighted as potential beneficiaries of the anti-involution policy [19]. Conclusion - The anti-involution policy is set to reshape the pig farming industry, addressing overcapacity and enhancing product quality while also impacting related sectors such as veterinary medicine. The overall economic environment and inflation dynamics will play a crucial role in shaping future market conditions and investment strategies [1][5][20].

Group 1 - The stock price of Tiankang Biological on July 29 closed at 6.50 yuan, down 0.11 yuan, a decrease of 1.66% from the previous trading day [1] - The trading volume on that day was 293,400 hands, with a transaction amount of 190 million yuan, and a turnover rate of 2.15% [1] - Tiankang Biological's main business includes feed, veterinary drugs, pig farming, and slaughter processing within the agricultural and animal husbandry industry chain [1] Group 2 - The company is a significant agricultural and animal husbandry enterprise in the Xinjiang region, involved in multiple fields such as feed production and animal vaccines [1] - According to the company's statement on the investor interaction platform, the cost of pig farming has decreased to 13 yuan per kilogram by early 2025, which is at an industry-leading level [1] - The company maintains cost control stability through optimizing feed formulas, improving production efficiency, and enhancing industry chain collaboration, while actively expanding sales in markets outside Xinjiang [1]